Table 1 Basic characteristics of included studies
Studies | Racial decent (country) | Study design | Therapeutic regimen | Sample size | Time of follow-up (months) | Random method | Withdraw & lost to follow-up | Blinding | Jadad Score |
|---|---|---|---|---|---|---|---|---|---|
Hogg 2015 [19] | Mixed (Canada) | RCT | MMF (25–36 mg/kg, max 2.0 g/day) | 22 | 6 | 1 | 1 | 1 | 3 |
Placebo | 22 | ||||||||
Liu 2014 [18] | Asians (China) | RCT | MMF (1.5Â g/day)Â +Â prednisone | 42 | 12 | 2 | 1 | 0 | 3 |
CTXÂ +Â prednisone | 42 | ||||||||
Liu 2010 [17] | Asians (China) | RCT | MMF (1.5Â g/day)Â +Â prednisone | 20 | 6 | 1 | 1 | 0 | 2 |
LEFÂ +Â prednisone | 20 | ||||||||
Bao 2007 | Asians (China) | RCT | MMF (2.0Â g/day)Â +Â prednisone | 18 | 12 | 1 | 1 | 0 | 2 |
CTXÂ +Â prednisone | 16 | ||||||||
Frich 2005 | Caucasians (America) | RCT | MMF (2.0Â g/day) | 17 | 24 | 2 | 1 | 2 | 5 |
Placebo | 15 | ||||||||
Tang 2005 [13] | Asians (China) | RCT | MMF (2.0Â g/day) | 20 | 18 | 1 | 1 | 1 | 3 |
Placebo | 20 | ||||||||
Baes 2004 | Caucasians (Belgium) | RCT | MMF (2.0Â g/day) | 21 | 36 | 1 | 1 | 1 | 3 |
Placebo | 13 | ||||||||
Chen 2002 [12] | Asians (China) | RCT | MMF (1.5Â g/day) | 18 | 18 | 1 | 1 | 0 | 2 |
prednisone | 21 |